1 / 14

Table S1

Table S1. Effect of LY341495, ketamine or NBQX on spontaneous locomotor activity. Table S1. Effect of LY341495, ketamine or NBQX on spontaneous locomotor activity

lofgren
Download Presentation

Table S1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Table S1 Effect of LY341495, ketamine or NBQX on spontaneous locomotor activity

  2. Table S1 Effect of LY341495, ketamine or NBQX on spontaneous locomotor activity For systemic administration, LY341495 (1, 3 mg/kg i.p.) or ketamine (30 mg/kg i.p.) was administered 30 min prior to the test. NBQX (10 mg/kg, s.c.) was administered 35 min prior to the test. For microinjection, LY341495 (0.03 pmol/side) or ketamine (3 nmol/side) was administered into the mPFC 30 min prior to the test. NBQX (0.03 nmol/side) was administered into the mPFC 35 min prior to the test. Vehicle A: 1/15 M phosphate buffer, Vehicle B: saline, Vehicle C: Ringer’s solution. Values indicate the mean ± S.E.M. (n = 6).

  3. Table S2 Effect of LY341495 or ketamine on the c-Fos immunoreactivity colocalized with 5-HT neuron cells in the dorsal raphe nucleus.

  4. Table S2 Effect of of LY341495 or ketamine on the c-Fos immunoreactivity colocalized with 5-HT neuron cells in the dorsal raphe nucleus. For microinjection, LY341495 (0.03 pmol/side) or ketamine (3 nmol/side) was administered into the mPFC 90 min prior to the test. NBQX (0.03 nmol/side) was administered into the mPFC 95 min prior to the test. For systemic administration, LY341495 (1, 3 mg/kg i.p.) or ketamine (30 mg/kg i.p.) was administered 90 min prior to the test. NBQX (10 mg/kg, s.c.) was administered 95 min prior to the test. →: not affected, ↑: increase, n.d.: not determined, (n = 6).

  5. Figure S1 (a) (b) (c) (e) (d)

  6. Figure S1 Effect of LY341495, ketamine, or paroxetine in the FST. Effect of LY341495 (a), ketamine (b) or paroxetine (c). LY341495 (0.1, 0.3, 1, 3 mg/kg i.p.), ketamine (3, 10, 30 mg/kg i.p.) or paroxetine (1, 3, 10 mg/kg i.p.) was administered 24 h prior to the test. Vehicle = (a): 1/15 M phosphate buffer (pH 8.0), (b): saline, (c): distilled water. Values indicate the mean ± S.E.M. ((a): n = 8, (b): n = 8, (c): n = 8). **p < 0.01, ***p < 0.001 compared with each vehicle (Dunnett’s test). Effect of 5-HT depletion on the antidepressant effect of LY341495 (d) or ketamine (e). LY341495 (3 mg/kg i.p.) or ketamine (30 mg/kg i.p.) was administered 24 h prior to the test. PCPA (300 mg/kg i.p.) was administered twice daily for 3 consecutive days until the day before the test. Vehicle = (d): 1/15 M phosphate buffer (pH 8.0), (e): saline. Values indicate the mean ± S.E.M. ((d): n = 10, (e): n = 10). ***p < 0.001 compared with 0.5% MC-treated each vehicle, ###p < 0.001 compared with 0.5% MC-treated agents ((d): LY341495, (e): ketamine) (LSD post hoc test).

  7. Figure S2 (a) (b) + 2.2 mm + 2.2 mm + 1.98 mm + 1.98 mm + 1.94 mm + 1.94 mm (d) (c)

  8. Figure S2 Effect of microinjection of LY341495 or ketamine into the mPFC in the FST. LY341495 (0.03 pmol/side) or ketamine (3 nmol/side) was administered into the mPFC 24 h prior to the test. Vehicle = (a): 0.1% 1/15 M phosphate buffer (pH 8.0) in Ringer’s solution, (b): Ringer’s solution. Values indicate the mean ± S.E.M. ((a): n = 7-8, (b): n = 8). ***p < 0.001 compared with each vehicle (Student’s t-test). (c, d) Location of the microinjection cannula tips in the mPFC included in the analyses of the data illustrated in ((c) = (a), (d) = (b). The line drawings are from Paxinos and Franklin (1997). The numbers to the right are the millimeters from the bregma. The open square represents the location of the microinjection cannula tips.

  9. Figure S3 + 2.2 mm + 1.98 mm + 1.94 mm

  10. Figure S3 Location of the microinjection cannula tips in the mPFC included in the analyses of the data illustrated in (Table S1). The line drawings are from Paxinos and Franklin (1997). The numbers to the right are the millimeters from the bregma. The open square represents the location of the microinjection cannula tips of the vehicleC, LY341495 and ketamine-microinjection group.

  11. Figure S4 Intra-mPFC (20×) c-Fos 5-HT c-Fos/5-HT Vehicle LY341495 Ketamine NBQX

  12. Figure S4 Effect of microinjection of LY341495 or ketamine on the c-Fos immunoreactivity colocalized with 5-HT neuron cells in the dorsal raphe nucleus. Confocal images of c-Fos (red), 5-HT cells (green) and double (5-HT-c-Fos, colocalization) immunoreactivities in the DRN at around -4,72 mm from bregma (Scale bar: 100 mm)

  13. Figure S5 (b) (a) c-Fos 5-HT c-Fos/5-HT c-Fos 5-HT c-Fos/5-HT Vehicle A (Intra-mPFC) + Vehicle C (i.p.) Vehicle A (Intra-mPFC) + Vehicle B (i.p.) Vehicle A(Intra-mPFC) + LY341495 (i.p.) Vehicle A(Intra-mPFC) + Ketamine (i.p.) NBQX (Intra-mPFC) + LY341495 (i.p.) NBQX (Intra-mPFC) + Ketamine (i.p.) (20×) (20×)

  14. Figure S5 Effect of microinjection of an AMPA receptor antagonist on LY341495 or ketamine-induced c-Fos immunoreactivity colocalized with 5-HT neuron cells in the dorsal raphe nucleus. (a, b) Confocal images of c-Fos (red), 5-HT cells (green) and double (5-HT-c-Fos, colocalization) immunoreactivities in the DRN at around -4,72 mm from bregma (Scale bar: (a, b) 100 mm).

More Related